Abstract: Objective To explore the association between interleukin-35(IL-35) polymorphisms and the risk of cognitive impairment in patients with coronary heart disease (CHD). Methods A total of 349 patients diagnosed as CHD in our hospital from February 2015 to October 2016 were enrolled in our case-control study. The cognitive function was evaluated by mini-mental state examination (MMSE). Patients were divided into control group (n=205) and cognitive impairment group (n=144) according to the MMSE results. Sequenom Mass array was used to analyze the genotypes of IL-35 SNPs (rs582054, rs2243115, rs428253, rs583911, rs568408 and rs4740), and ELISA was used to detect the plasma level of IL-35, while other parameters were examined by standard protocol in the laboratory of the People’s Hospital of Guangxi Zhuang autonomous region. The binary Logistic regression model was used to reveal the associations between IL-35 polymorphisms and the risk of cognitive impairment in CHD. Results There was no significant difference in plasma level of IL-35 between two groups [42.26 (17.19, 203.06) ng/L vs. 40.60 (22.69, 105.65) ng/L, Z=0.384, P＞0.05]. No significant association was found between IL-35 polymorphisms and the risk of cognitive impairment in CHD patients. After the adjustment of risk factors, no significant association was found between IL-35 polymorphisms and the risk of cognitive impairment in CHD patients. Conclusion There is no relationship between IL-35 polymorphisms and the risk of cognitive impairment in CHD patients. It is still necessary to expand the sample size and explore its mechanism in the future.

Key words: interleukin-35, polymorphism, single nucleotide, coronary heart disease, cognitive impairment